Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Etelcalcetide (Primary) ; Cinacalcet
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Amgen
- 31 May 2018 Status changed from not yet recruiting to recruiting.
- 30 Jan 2018 Planned End Date changed from 19 Jul 2019 to 29 Jul 2019.
- 30 Jan 2018 Planned primary completion date changed from 19 Jul 2019 to 29 Jul 2019.